Squamous cell carcinoma - Плоскоклітинний Рак
☆ За результатами дослідження Stiftung Warentest у Німеччині за 2022 рік рівень задоволеності споживачів ModelDerm був лише трохи нижчим, ніж платними телемедичними консультаціями.
Squamous cell carcinoma well differentiated ― Спостерігається прилеглий актинічний кератоз.
References
Squamous cell carcinoma (SCC) є другим за поширеністю раком шкіри в Сполучених Штатах після basal cell carcinoma. Зазвичай починається з передракових утворень, які називаються actinic keratosis , і може поширюватися на інші частини тіла. Основною причиною є вплив ультрафіолетового (УФ) випромінювання сонця, яке накопичується з часом. Лікування зазвичай включає хірургічне видалення, особливо для SCC на голові та шиї. Променева терапія є варіантом для літніх пацієнтів або тих, хто не може зробити операцію. Імуносупресія підвищує ризик SCC. Хоча це рідко, SCC може поширюватися, особливо у пацієнтів з ослабленою імунною системою. Регулярні огляди та захист від сонця важливі для тих, хто має СКК.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) є другим за поширеністю раком серед людей, і його кількість зростає. Хоча CSCC зазвичай має доброякісну клінічну поведінку, він може поширюватися як локально, так і на інші частини тіла. Вчені визначили конкретні шляхи розвитку CSCC, що веде до нових методів лікування. Велика кількість мутацій і підвищений ризик у пацієнтів з імуносупресією спонукали до розвитку імунотерапії. У цьому огляді розглядаються генетичні корені CSCC і новітні методи лікування, спрямовані на конкретні молекули та імунну систему.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Діагностика та лікування
#Dermoscopy
#Skin biopsy